Anticardiolipin antibodies in Behçet's disease: a reassessment.
OBJECTIVE
To assess the frequency and clinical relevance of anticardiolipin antibodies (aCL) in Behçet's disease (BD).


METHODS
IgG, IgM and IgA aCL isotypes were investigated by ELISA in 128 patients with BD, 143 healthy controls and 20 systemic lupus erythematosus (SLE) patients.


RESULTS
The IgA binding index (BI) was slightly elevated in BD compared with healthy controls (120+/-53 vs 107+/-46, P=0.02), whereas IgG and IgM aCL levels were not significantly different (IgG, BD 2.5+/-2.4 G phospholipid (GPL), healthy controls 2.8+/-3.6 GPL, P=0.6; IgM, BD 0.7+/-0.9 M phospholipid (MPL), healthy controls 0.9+/-1.3 MPL, P=0.6). The frequency of aCL positivity was 7% in BD (IgG 0.8%, IgM 1.6%, IgA 4.6%), 50% in SLE and 5.6% in healthy controls. IgA BI was elevated in the HLA-B5-negative group compared with HLA-B5-positive patients (P<0.005). In a literature review, the frequency of aCL was found to be 9.5% in studies from Turkey compared with 25.5% in other series (P<0.0001).


CONCLUSIONS
These results do not suggest a primary role for aCL in BD. A significantly lower frequency of aCL in Turkish BD patients than in other series indicate that regional determinants, whether environmental or genetic, might also play a role in controlling aCL production in BD.
Tokay
S
S
Department of Rheumatology, Faculty of Medicine, Marmara University, Istanbul, Turkey.
Direskeneli
H
H
Yurdakul
S
S
Akoglu
T
T
D000328:Adult; D017153:Antibodies, Anticardiolipin / Q000097:blood*; D001528:Behcet Syndrome / Q000097:blood*; D005260:Female; D006801:Humans; D008297:Male
D017153:Antibodies, Anticardiolipin